Advances in Pharmacological and Pharmaceutical Sciences

Advances in Pharmacological and Pharmaceutical Sciences / 2011 / Article
Special Issue

GABAA Receptor Subtypes: Novel Targets for Novel Medicines

View this Special Issue

Review Article | Open Access

Volume 2011 |Article ID 790590 |

Adam C. Errington, David W. Cope, Vincenzo Crunelli, "Augmentation of Tonic GABAA Inhibition in Absence Epilepsy: Therapeutic Value of Inverse Agonists at Extrasynaptic GABAA Receptors", Advances in Pharmacological and Pharmaceutical Sciences, vol. 2011, Article ID 790590, 12 pages, 2011.

Augmentation of Tonic GABAA Inhibition in Absence Epilepsy: Therapeutic Value of Inverse Agonists at Extrasynaptic GABAA Receptors

Academic Editor: Keith Wafford
Received17 Mar 2011
Accepted16 May 2011
Published05 Sep 2011


It is well established that impaired GABAergic inhibition within neuronal networks can lead to hypersynchronous firing patterns that are the typical cellular hallmark of convulsive epileptic seizures. However, recent findings have highlighted that a pathological enhancement of GABAergic signalling within thalamocortical circuits is a necessary and sufficient condition for nonconvulsive typical absence seizure genesis. In particular, increased activation of extrasynaptic GABAA receptors (eGABAAR) and augmented “tonic” GABAA inhibition in thalamocortical neurons have been demonstrated across a range of genetic and pharmacological models of absence epilepsy. Moreover, evidence from monogenic mouse models (stargazer/lethargic) and the polygenic Genetic Absence Epilepsy Rats from Strasbourg (GAERS) indicate that the mechanism underlying eGABAAR gain of function is nonneuronal in nature and results from a deficiency in astrocytic GABA uptake through the GAT-1 transporter. These results challenge the existing theory that typical absence seizures are underpinned by a widespread loss of GABAergic function in thalamocortical circuits and illustrate a vital role for astrocytes in the pathology of typical absence epilepsy. Moreover, they explain why pharmacological agents that enhance GABA receptor function can initiate or exacerbate absence seizures and suggest a potential therapeutic role for inverse agonists at eGABAARs in absence epilepsy.

1. Introduction

Typical absence epilepsy is characterised by the regular occurrence of nonconvulsive seizures that result in periods of sudden and brief (average 10 seconds, range 4–40 seconds) loss of consciousness. In the electroencephalogram (EEG), human absence seizures are typified by the appearance of generalized, synchronous, and bilateral “spike (or polyspike) and slow wave discharges” (SWD) occurring at frequencies between 2.5–4 Hz [1, 2]. Although typical absence seizures are significant clinical features of many generalized idiopathic epilepsies (IGEs), as defined by the classification of the International League Against Epilepsy (ILAE) [3], they are the only neurological symptom presented in childhood absence epilepsy (CAE). CAE has an annual incidence of approximately 2–8 per 100,000 children under 16 years of age, with seizure onset typically occurring between 3 and 8 years of age and seizure frequency often as high as several hundred events per day [2]. Absence seizures associated with CAE are not triggered by visual or other sensory stimuli and are not usually associated with neurometabolic or neurophysiological deficits, a factor which is thought to contribute to ~70% spontaneous remission rates in adolescence [2, 4]. Nonetheless, in this pure absence epilepsy phenotype, there is a consensus, based upon older invasive studies and more recent imaging investigations, that seizure genesis and propagation occur as a result of aberrant electrical activity in reciprocally connected thalamic and cortical regions (i.e., thalamocortical circuits) without significant involvement of other brain areas including hippocampus and limbic regions which are often associated with convulsive seizures [59]. In fact, recent observations in humans suggest that seizure genesis occurs due to paroxysmal activation of discrete frontal and parietal cortical territories prior to spread into other cortical and thalamic regions [58]. This review will, therefore, focus on the key cellular elements of thalamocortical circuits and in particular upon thalamocortical neurons.

γ-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter in the brain, and its actions are mediated largely by a family of ubiquitously expressed ligand-gated ion channels known as GABAA receptors [10]. GABAA receptors are pentameric assemblies comprising several distinct subunits which open upon GABA binding leading to an increase in membrane permeability to both chloride and bicarbonate ions [11]. Typically this occurs when GABA is released from presynaptic terminals causing a transient rise in GABA concentration within the synaptic cleft and activation of postsynaptic receptors. The resulting brief change in membrane conductance underlies “phasic” GABAAergic inhibition and generation of the “classical” inhibitory postsynaptic potential (IPSP). However, it has come to light relatively recently that GABAA receptor activation can occur in a much more spatially and temporally diffuse manner [10]. It has been demonstrated in several brain regions including the cerebellum [12], hippocampus [13], and thalamus [1416] that very low (nM) concentrations of GABA, which are found in the extracellular space, can persistently activate a population of nonsynaptic GABAA receptors resulting in a “tonic” increase in membrane conductance. These peri- or extrasynaptic GABAA receptors (eGABAARs) differ from their synaptic counterparts in having a significantly higher affinity for GABA as well as markedly slower rates of desensitization [10, 1719] although it has been recently demonstrated in the visual thalamus that significant desensitization of eGABAARs can occur at ambient GABA concentrations [20]. The divergence in the properties of synaptic GABAARs versus eGABAARs is conferred by receptor subunit composition, in particular, the inclusion of the δ subunit in the case of dentate gyrus granule cells (DGCs), cerebellar granule cells (CGCs), thalamocortical neurons and some cortical neurons [1316, 21, 22], and α5 subunits in CA1 and CA3 hippocampal pyramidal cells [2325]. Nineteen GABAA receptor subunits have been cloned from the mammalian CNS (α(1–6), β(1–3), γ(1–3), δ, ε, θ, π, ρ(1–3)) offering the potential for an enormous heterogeneity in GABAA receptor assembly. In reality however, only about twenty to thirty of the potential combinations have been shown to exist in the brain. The most commonly expressed subunit combination is α1, β2, γ2 (with stoichiometry of 2α and 2β subunits and a single γ subunit [26, 27]) whilst other common arrangements include α2β3γ2 and α3β3γ2. Significantly, light microscopic immunofluorescence and EM immunogold methods have established that the postsynaptic densities of GABAergic synapses are highly enriched with receptors including α(1–3), α6, β(2-3), and γ2 subunits [28, 29] suggesting that these subunits form the GABAA receptors responsible for classical “phasic” inhibition. However, in contrast to the aforementioned subunits which are enriched in the postsynaptic density but also abundant at extrasynaptic locations [30, 31], some GABAA receptor subunits, especially δ, are not found in the synapse and are exclusively peri- or extrasynaptically located [21]. Extrasynaptic receptors containing the δ subunit are commonly found to coassemble with α4 or α6 subunits (α4/α6βXδ) whilst α5-containing receptors are also mostly extrasynaptic despite usually containing the typically synaptically located γ2 subunit (α5βXγ2). A recent study by Kasugai et al. [32] has demonstrated the presence of α1 and α2 subunits as well as β3 subunits at extrasynaptic locations on the soma of CA1 pyramidal neurons suggesting these subunits may also contribute to eGABAAR signalling and perhaps confer specific pharmacological properties.

Thalamocortical (TC) neurons of the dorsal lateral geniculate nucleus (dLGN, visual thalamus) [14], the ventrobasal nuclei (VB, somatosensory thalamus) [1416], and the medial geniculate body (MGB, auditory thalamus) [33] of rodents have been demonstrated in vitro to have robust GABAergic tonic currents. In voltage-clamped TC neurons, application of the GABAA receptor antagonist SR-95531 not only completely blocks the phasic inhibitory postsynaptic currents (IPSCs) but also produces a reduction in input conductance accompanied by a decrease in current variance that is indicative of block of tonically active eGABAARs. In the thalamus, it has been estimated that approximately 80–90% of total GABAA receptor-mediated inhibition occurs through tonic currents resulting from activation of extrasynaptic GABAARs [14, 16]. In fact, it has been suggested that tonic conductance in TC neurons (when normalized to whole cell capacitance) may be larger than in other regions expressing eGABAARs including the cerebellum and dentate gyrus [16]. In all of the previously described thalamic nuclei, there is a high expression of the GABAA receptor δ-subunit [22, 3335], and several studies have shown, using selective pharmacological agents [1416], δ-subunit knock-out (δ−/−) [36] and α4-subunit knock-out (α4−/−) [37] mice that the thalamic tonic current is mediated largely by α4β2δ subunit-containing receptors. In particular, eGABAARs in the thalamic nuclei are highly sensitive to the potent and selective activator of α4-δ-containing [38] receptors 4,5,6,7-tetrahydroisoxazolo[5,4-c]-pyridin-3-ol (THIP, Gaboxadol) [1416, 37] as well as ethanol [39], taurine [40], and the anaesthetic isoflurane [41], all of which act to enhance tonic inhibition. Conversely, the α1-selective agent zolpidem and the nonselective benzodiazepine midazolam increase the decay time of sIPSCs in VB neurons without effects on tonic currents and the inverse agonist Ro 15-4513, a potent activator of α4-γ2 subunit-containing receptors [38], also had no effect of tonic current in VB [15]. Functionally, eGABAARs in the thalamus have been suggested to play a role in switching the behavioural state-dependent TC neuron firing modes [14] and modulating the temporal precision of rebound low-threshold Ca2+ spikes (LTS) [34]. Furthermore, tonic inhibition in TC neurons is likely to play a significant role in the modulation of slow wave sleep (SWS) activity given the integral role of TC neurons in generating low-frequency (<4 Hz) oscillations in corticothalamic circuits [14, 16]. However, the potential importance of eGABAARs in pathological seizure activity associated with typical absence epilepsy has only recently been elucidated.

2. Enhanced Tonic GABAA Inhibition in Thalamocortical Neurons of Genetic Absence Epilepsy Models

It has been demonstrated in vitro using several different genetic animal models of absence seizures that the tonic GABAA current in TC neurons of the VB thalamus is enhanced in animals displaying an epileptic phenotype compared to their respective nonepileptic control animals (Figure 1) [36]. This was first shown in the polygenic GAERS model but has subsequently also been demonstrated for various mice models with known, but divergent, spontaneous monogenic mutations, including stargazer and lethargic mice. In GAERS animals, there is a clear developmental profile for this increased GABAergic function (Figure 1(a)). Up to postnatal day sixteen, the tonic current in VB of GAERS is similar to that of the nonepileptic control (NEC) strain. However, in the 24 hour period between the postnatal day 16-17, there is a significant (almost doubling) increase in the amplitude of the tonic current in VB TC neurons of the epileptic animals [36] that remains elevated well past the time of seizure onset (around the postnatal day 30 in this strain). These data suggest that, rather than occurring as a consequence of seizure onset, the pathological enhancement of tonic GABA inhibition during development in GAERS may be proepileptogenic. Moreover, despite the full developmental profile for the monogenic lethargic and stargazer mice being unknown, it is clear in these models that a significant enhancement of tonic current in TC neurons is present after seizure onset, (Figure 1(b)) [36]. In contrast, no tonic GABAA current is detected in the GABAergic NRT neurons of GAERS or NEC animals (unpublished observation) as is indeed the case in normal Wistar rats [14].

The pathological augmentation of tonic GABAA currents in TC neurons of genetic absence models is, however, not due to increased vesicular GABA release, overexpression of δ-subunit containing eGABAARs, or misexpression of synaptic GABAARs but results from a dysfunction of GABA re-uptake by the transporter GAT-1 [36]. In fact, despite being far less abundant in the thalamus than GAT-3 [42], GAT-1 appears to play a major role in the regulation of extrasynaptic GABA concentration and activation of eGABAARs [36]. In acute brain slices prepared from both GAERS and stargazer animals, block of GAT-1 using the specific antagonist NO711 produced no effect upon the magnitude of tonic current observed in VB TC neurons, (Figures 1(c), 1(d), and 1(e)). In marked contrast, the block of GAT-1 in neurons of nonepileptic mice and rats facilitated a significant enhancement of tonic current that reached levels similar to those found in neurons from epileptic animals, (Figures 1(c), 1(d), and 1(e)). Furthermore, in nonepileptic animals, blockade of GAT-3 using SNAP5114 resulted in an increase in tonic current that was significantly less than that observed in GAERS or stargazer suggesting that the ability of GAT-1 to compensate for the loss of GAT-3 is erased in the epileptic strains, (Figures 1(c), 1(d), and 1(e)). These findings are made all the more significant by the fact that expression of both GAT-1 and GAT-3 in the thalamus appears to occur exclusively in nonneuronal cells, specifically astrocytes [42, 43]. A malfunction in GAT-1 also underlies the increased tonic GABAA current in TC neurons of lethargic mice [36]. In contrast to GAERS and stargazer mice; however, the action of this transporter is not inhibited in lethargic mice but appears to be reversed. These data expand upon previous findings that demonstrated a reduction in GABA uptake by GAT-1 [44] and increased levels of extracellular GABA [45] in the VB thalamus of GAERS compared to NEC. Moreover, NO711 increases tonic GABAA current by a similar amount in dentate gyrus granule cells of GAERS and NEC [36], indicating that GAT-1 activity is not compromised in a brain area that does not participate in the generation of typical absence seizures and where the distribution of this transporter is primarily neuronal. Indeed, the basal tonic current of dentate gyrus granule cells is not different between GAERS and NEC [36], and in stargazer mice, tonic current in both DGCs and CGCs is actually reduced compared to WT littermates [46]. Interestingly, it has been demonstrated previously in CGCs of GABAAR α1 subunit knock-out (α1−/−) mice that tonic currents in these neurons are also enhanced via a reduction of GAT activity that is not due to reduction in GAT-1 or GAT-3 expression or increased expression of either α6 or δ subunit-containing receptors [47].

In summary; therefore, genetic models of typical absence seizures (i.e., GAERS, stargazer, and lethargic mice) show a brain region-specific enhancement of tonic GABAA current, which in TC neurons is due to increased extracellular GABA level that in turn results from a malfunction in GABA uptake by astrocytic GAT-1.

3. Pharmacological Models of Typical Absence Epilepsy and the Role of GABAB Receptors

As well as resulting from genetic modifications, SWDs can be generated in genetically “normal” animals through administration of various pharmacological agents. The best-established pharmacological model of typical absence seizures is achieved by the systemic administration of γ-hydroxybutyric acid (GHB) [4850]. However, it has been known for some time that systemic administration of THIP, a selective agonist at δ subunit-containing extrasynaptic GABAARs, also elicits SWDs in normal animals, (Figure 2(a)) [51]. In the context of the involvement of enhanced thalamic tonic GABAA inhibition in several genetic models of absence epilepsy, the pharmacological induction of seizures by THIP becomes more readily explainable. This is because, as previously disclosed, THIP can potently enhance tonic GABAA currents of TC neurons in nonepileptic rats, (Figure 2(b)), [36] and mice [15, 16], thus mimicking the enhanced thalamic tonic inhibition observed in genetic models. On the other hand, the effects of GHB, which does not bind to GABAARs and is believed to elicit absence seizures by activation of GABABRs [50], become more difficult to interpret in light of the apparent necessity for enhanced eGABAAR signalling during SWDs. However, it has now been demonstrated in brain slices of Wistar rats that GHB enhances tonic GABAA currents in TC neurons, (Figure 2(c)) [36]. The effects on tonic GABAergic inhibition in vitro are dose dependent with concentrations used reflecting those that are required to elicit absence seizures in vivo, (Figure 2(d)) [52]. Moreover, the effects of GHB are not due to nonspecific binding interactions since the GHB-mediated enhancement of tonic current is negated by the GABABR antagonist CGP55845, (Figure 2(d)). In fact, application of CGP55845 alone significantly reduces the tonic GABAA current amplitude in TC neurons of Wistar rats to 74% of the control values, indicating that facilitation of extrasynaptic GABAARs by GABABRs contributes approximately one quarter of the tonic GABAA current in normal rats. Importantly, CGP55845 also reduces the tonic current in GAERS, stargazer, and lethargic mice to about 55, 65, and 57% of control, (Figure 2(e)), respectively, [36] suggesting that facilitation of extrasynaptic GABAAR function by GABABR activation contributes up to half of the pathologically enhanced tonic current in these genetic models.

This GHB-mediated enhancement of thalamic tonic currents is fascinating in the context of another genetic disorder related to GABAergic system function. Succinic semialdehyde dehydrogenase (SSADH) deficiency is an autosomal recessively inherited disorder that results in loss of activity in SSADH (an enzyme responsible for metabolism of GABA), reduced GABA breakdown, and excessive accumulation of both GABA and GHB in the cerebrospinal fluid [53, 54]. Clinical symptoms are varied but include delayed intellectual, speech and language development, ataxia and, significantly, generalised absence seizures [5557]. Using a recently developed SSADH knock-out (SSADH−/−) mouse [53, 58, 59], we have been able to demonstrate that in these animals, which replicate the epileptic phenotype displayed in humans with SSADH deficiency, there is a significant enhancement of tonic GABAA currents in TC neurons compared to their WT counterparts, Figures 3(a) and 3(c) [60]. Moreover, as previously described for other genetic models of absence seizures, a large proportion of the enhanced tonic current is sensitive to block by GABABR antagonists further supporting the role of these metabotropic receptors in the pathology of absence seizures, (Figures 3(b) and 3(d)) [60].

In summary; therefore, a GAT-1 malfunction in thalamic astrocytes of mouse and rat genetic models leads to an increase in ambient GABA in the sensory thalamus, which in turn elicits an enhancement in tonic GABAA inhibition through direct activation of extrasynaptic GABAARs and indirect facilitation of extrasynaptic GABAARs via activation of GABABRs.

4. Enhanced Tonic GABAA Inhibition of TC Neurons Is Necessary and Sufficient for Typical Absence Seizure Generation

As previously described, SWDs of typical absence epilepsy appear to be initiated in deep layers (V/VI) of the cortex where intracellular recordings show rhythmic paroxysmal depolarisations occurring in phase with the EEG spike [6163]. The action potentials associated with these synchronous depolarisations in turn provide strong rhythmic input to thalamic nuclei. In NRT neurons in vivo, the strong converging corticothalamic input that result from cortical volleys during SWDs produces bursts of excitatory postsynaptic potentials (EPSPs) that trigger T-type Ca2+-channel-mediated LTS and bursts of action potentials. In contrast, TC neurons receive both monosynaptic excitation directly from corticothalamic inputs and disynaptic inhibition via the NRT. In vivo intracellular recordings made in GAERS have shown that during ictal activity TC neurons typically receive sequences of one EPSP plus four to six IPSPs arriving in phase with each EEG spike and that action potential firing is rare [62, 64]. This is likely due to the much stronger corticothalamic excitatory inputs into NRT neurons compared to TC neurons [65] and the robust nature of the LTS-driven action potential bursts of NRT neurons [62, 64]. Thus, it is highly probable although it remains to be directly demonstrated that strong GABAergic input into TC neurons during SWDs produces activation of eGABAARs and that the corresponding increase in tonic current contributes to the observed downregulation of TC neuron output during ictal activity.

To assess the impact that the enhanced tonic GABAA current of TC neurons might have in the expression of absence seizures, experiments in freely moving animals are required. Under these conditions, both the behavioural and EEG components of the seizures can be assessed, and data are not confounded by the concomitant use of anaesthetics and/or analgesics. Thus, unrestrained GAT-1 KO mice (GAT-1−/−), which have not undergone any pharmacological treatment and whose TC neurons display enhanced tonic GABAA currents in vitro express ethosuximide-sensitive typical absence seizures (Figures 4(a), 4(b) and 4(c)) [36]. Furthermore, the direct injection of the selective GAT-1 blocker NO-711 into the VB by reverse microdialysis initiates ethosuximide-sensitive typical absence seizures in previously nonepileptic Wistar rats (Figures 4(d) and 4(e)) [36]. On the other hand, in δ−/− mice, which exhibit a nearly ablated tonic GABAA inhibition in TC neurons (Figure 5(a)), systemic administration of GHB fails to induce absence seizures (Figures 5(b) and 5(c)) [36]. Intrathalamic injection of a δ subunit-specific antisense oligodeoxynucleotide in GAERS strongly decreases both the tonic GABAA current and spontaneous seizures 1-2 days after injection, whereas a missense oligodeoxynucleotide has no effect (Figures 5(d), 5(e), and 5(f)) [36]. Finally, intrathalamic administration of THIP in normal Wistar rats elicits absence seizures in a concentration-dependent manner, which as expected are blocked by systemic administration of ethosuximide [36]. Taken together, these data show that enhanced tonic GABAA inhibition in TC neurons is both necessary and sufficient for the generation of typical absence seizures.

5. Conclusions and Future Perspectives

Augmented tonic GABAA inhibition in TC neurons represents the first potential molecular mechanism that is common to both well-established pharmacological and genetic models of typical absence seizures. Despite having a range of divergent genetic mutations, GAERS (polygenic), stargazer (Ca2+ channel γ2 subunit, TARP-γ2), lethargic (Ca2+ channel β4 subunit), SSADH−/− and GAT-1−/− mice all display SWDs characteristic of typical absence epilepsy, whereas in δ−/− mice drugs that commonly produce SWDs are ineffective. Importantly, because powerful GABAA IPSPs can be recorded in the vast majority of TC neurons during absence seizures in vivo [64, 66], these findings also indicate that model systems that aim to reproduce typical absence seizures by blocking GABAARs of TC neurons are inherently flawed.

The discovery of a malfunction in GAT-1 as the underlying abnormality that produces increased tonic GABAA inhibition in TC neurons of genetic absence models shifts the emphasis from a neuronal to an astrocytic aetiology for this type of nonconvulsive epilepsy. Impaired GAT-1 activity in GAERS is not caused by decreased thalamic or cortical expression of GAT-1 mRNA or protein levels. Also, no genetic variants are present in GAT-1 cDNA from GAERS, stargazer, or lethargic mice nor are the mutations responsible for absence seizures in stargazer and lethargic mice present in GAERS. Future studies, therefore, may investigate whether GAT-1 is unable to reach the outer astrocytic membrane and/or whether there are abnormalities in its phosphorylation processes.

Experimental typical absence seizures can be elicited or aggravated by selective GABABR agonists and can be blocked by selective GABABR antagonists, applied either systemically or intrathalamically. Because about 50% of the tonic GABAA current observed in TC neurons of GAERS, stargazer, and lethargic and SSADH−/− mice is abolished by a GABAB antagonist [36, 60], the behavioural and EEG effects of selective GABAB drugs on typical absence seizures can no longer be simply explained by the ability of these drugs to affect GABAB IPSPs and/or presynaptic GABABRs but should also take into account the positive modulation by GABABRs of the tonic GABAA inhibition in TC neurons.

From a clinical perspective, it is important to stress that all the results reviewed above provide a mechanistic explanation for the aggravation of absence seizures that is observed in humans and experimental animals following either systemic or intrathalamic administration of drugs that increase GABA levels, including tiagabine, a GABA uptake blocker, and vigabatrin, a GABA transaminase blocker [6770]. Thus, the classical approach of treating seizures by increasing inhibition through positive modulation of GABA-ergic neurotransmission is particularly ineffective in absence epilepsy. In this circumstance, a selective reduction of tonic GABAA inhibition in thalamic neurons presents perhaps the best possible therapeutic intervention. Intriguingly, a recent study demonstrated that excessive tonic GABAAergic inhibition is also a feature of cortical neurons surrounding the infarct site (peri-infarct) after induction of stroke in experimental models (in this model, a reduction in GAT-3/4 expression in neurons was observed) [71]. In the motor cortex, where the stroke was induced, eGABAARs largely contain α5 and δ subunits. The α5 selective benzodiazepine inverse agonist L655,708 produced a significant reduction in the tonic current amplitude in peri-infarct neurons of slices from poststroke animals as well as improving the performance of animals in an in vivo motor task [71]. In a similar manner, the gain of function of eGABAARs in typical absence seizures provides compelling preclinical data for the development of inverse agonists selective for α4-δ subunit containing GABAARs which may have potential therapeutic value in this type of nonconvulsive epilepsy.


  1. M. Avoli, M. A. Rogawski, and G. Avanzini, “Generalized epileptic disorders: an update,” Epilepsia, vol. 42, no. 4, pp. 445–457, 2001. View at: Publisher Site | Google Scholar
  2. V. Crunelli and N. Leresche, “Childhood absence epilepsy: genes, channels, neurons and networks,” Nature Reviews Neuroscience, vol. 3, no. 5, pp. 371–382, 2002. View at: Publisher Site | Google Scholar
  3. J. Roger, F. E. Dreifuss, M. Martinez-Lage et al., “Proposal for revised classification of epilepsies and epileptic syndromes,” Epilepsia, vol. 30, no. 4, pp. 389–399, 1989. View at: Google Scholar
  4. H. Blumenfeld, “Cellular and network mechanisms of spike-wave seizures,” Epilepsia, vol. 46, no. 9, pp. 21–33, 2005. View at: Publisher Site | Google Scholar
  5. M. D. Holmes, M. Brown, and D. M. Tucker, “Are “generalized” seizures truly generalized? Evidence of localized mesial frontal and frontopolar discharges in absence,” Epilepsia, vol. 45, no. 12, pp. 1568–1579, 2004. View at: Publisher Site | Google Scholar
  6. K. Hamandi, A. Salek-Haddadi, H. Laufs et al., “EEG-fMRI of idiopathic and secondarily generalized epilepsies,” NeuroImage, vol. 31, no. 4, pp. 1700–1710, 2006. View at: Publisher Site | Google Scholar
  7. X. Bai, M. Vestal, R. Berman et al., “Dynamic time course of typical childhood absence seizures: EEG, behavior, and functional magnetic resonance imaging,” Journal of Neuroscience, vol. 30, no. 17, pp. 5884–5893, 2010. View at: Publisher Site | Google Scholar
  8. I. Westmijse, P. Ossenblok, B. Gunning, and G. van Luijtelaar, “Onset and propagation of spike and slow wave discharges in human absence epilepsy: a MEG study,” Epilepsia, vol. 50, no. 12, pp. 2538–2548, 2009. View at: Google Scholar
  9. J. P. Szaflarski, M. DiFrancesco, T. Hirschauer et al., “Cortical and subcortical contributions to absence seizure onset examined with EEG/fMRI,” Epilepsy and Behavior, vol. 18, no. 4, pp. 404–413, 2010. View at: Publisher Site | Google Scholar
  10. M. Farrant and Z. Nusser, “Variations on an inhibitory theme: phasic and tonic activation of GABA A receptors,” Nature Reviews Neuroscience, vol. 6, no. 3, pp. 215–229, 2005. View at: Publisher Site | Google Scholar
  11. M. Chebib and G. A. R. Johnston, “GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology,” Journal of Medicinal Chemistry, vol. 43, no. 8, pp. 1427–1447, 2000. View at: Publisher Site | Google Scholar
  12. S. G. Brickley, S. G. Cull-Candy, and M. Farrant, “Development of a tonic form of synaptic inhibition in rat cerebellar granule cells resulting from persistent activation of GABAA receptors,” Journal of Physiology, vol. 497, no. 3, pp. 753–759, 1996. View at: Google Scholar
  13. Z. Nusser and I. Mody, “Selective modulation of tonic and phasic inhibitions in dentate gyrus granule cells,” Journal of Neurophysiology, vol. 87, no. 5, pp. 2624–2628, 2002. View at: Google Scholar
  14. D. W. Cope, S. W. Hughes, and V. Crunelli, “GABAA receptor-mediated tonic inhibition in thalamic neurons,” Journal of Neuroscience, vol. 25, no. 50, pp. 11553–11563, 2005. View at: Publisher Site | Google Scholar
  15. F. Jia, L. Pignataro, C. M. Schofield, M. Yue, N. L. Harrison, and P. A. Goldstein, “An extrasynaptic GABAA receptor mediates tonic inhibition in thalamic VB neurons,” Journal of Neurophysiology, vol. 94, no. 6, pp. 4491–4501, 2005. View at: Publisher Site | Google Scholar
  16. D. Belelli, D. R. Peden, T. W. Rosahl, K. A. Wafford, and J. J. Lambert, “Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics,” Journal of Neuroscience, vol. 25, no. 50, pp. 11513–11520, 2005. View at: Publisher Site | Google Scholar
  17. S. G. Brickley, S. G. Cull-Candy, and M. Farrant, “Single-channel properties of synaptic and extrasynaptic GABAA receptors suggest differential targeting of receptor subtypes,” Journal of Neuroscience, vol. 19, no. 8, pp. 2960–2973, 1999. View at: Google Scholar
  18. D. Bai, G. Zhu, P. Pennefather, M. F. Jackson, J. F. Macdonald, and B. A. Orser, “Distinct functional and pharmacological properties of tonic and quantal inhibitory postsynaptic currents mediated by γ-aminobutyric acidA receptors in hippocampal neurons,” Molecular Pharmacology, vol. 59, no. 4, pp. 814–824, 2001. View at: Google Scholar
  19. J. Y. T. Yeung, K. J. Canning, G. Zhu, P. Pennefather, J. F. MacDonald, and B. A. Orser, “Tonically activated GABAA receptors in hippocampal neurons are high-affinity, low-conductance sensors for extracellular GABA,” Molecular Pharmacology, vol. 63, no. 1, pp. 2–8, 2003. View at: Publisher Site | Google Scholar
  20. D. P. Bright, M. Renzi, J. Bartram et al., “Profound desensitization by ambient GABA limits activation of δ-containing GABAA receptors during spillover,” Journal of Neuroscience, vol. 31, no. 2, pp. 753–763, 2011. View at: Publisher Site | Google Scholar
  21. Z. Nusser, W. Sieghart, and P. Somogyi, “Segregation of different GABAA receptors to synaptic and extrasynaptic membranes of cerebellar granule cells,” Journal of Neuroscience, vol. 18, no. 5, pp. 1693–1703, 1998. View at: Google Scholar
  22. S. Pirker, C. Schwarzer, A. Wieselthaler, W. Sieghart, and G. Sperk, “GABAA receptors: immunocytochemical distribution of 13 subunits in the adult rat brain,” Neuroscience, vol. 101, no. 4, pp. 815–850, 2000. View at: Publisher Site | Google Scholar
  23. V. B. Caraiscos, E. M. Elliott, K. E. You-Ten et al., “Tonic inhibition in mouse hippocampal CA1 pyramidal neurons is mediated by α5 subunit-containing γ-aminobutyric acid type A receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 10, pp. 3662–3667, 2004. View at: Publisher Site | Google Scholar
  24. G. Sperk, C. Schwarzer, K. Tsunashima, K. Fuchs, and W. Sieghart, “GABAA receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits,” Neuroscience, vol. 80, no. 4, pp. 987–1000, 1997. View at: Publisher Site | Google Scholar
  25. J. Glykys and I. Mody, “Hippocampal network hyperactivity after selective reduction of tonic inhibition in GABAA receptor α5 subunit-deficient mice,” Journal of Neurophysiology, vol. 95, no. 5, pp. 2796–2807, 2006. View at: Publisher Site | Google Scholar
  26. S. J. Farrar, P. J. Whiting, T. P. Bonnert, and R. M. McKernan, “Stoichiometry of a ligand-gated ion channel determined by fluorescence energy transfer,” Journal of Biological Chemistry, vol. 274, no. 15, pp. 10100–10104, 1999. View at: Publisher Site | Google Scholar
  27. P. J. Whiting, T. P. Bonnert, R. M. McKernan et al., “Molecular and functional diversity of the expanding GABA-A receptor gene family,” Annals of the New York Academy of Sciences, vol. 868, pp. 645–653, 1999. View at: Publisher Site | Google Scholar
  28. A. M. Craig, C. D. Blackstone, R. L. Huganir, and G. Banker, “Selective clustering of glutamate and γ-aminobutyric acid receptors opposite terminals releasing the corresponding neurotransmitters,” Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 26, pp. 12373–12377, 1994. View at: Publisher Site | Google Scholar
  29. P. Somogyi, J. M. Fritschy, D. Benke, J. D. B. Roberts, and W. Sieghart, “The γ2 subunit of the GABAA receptor is concentrated in synaptic junctions containing the α1 and β2/3 subunits in hippocampus, cerebellum and globus pallidus,” Neuropharmacology, vol. 35, no. 9-10, pp. 1425–1444, 1996. View at: Publisher Site | Google Scholar
  30. Z. Nusser, J. D. B. Roberts, A. Baude, J. G. Richards, and P. Somogyi, “Relative densities of synaptic and extrasynaptic GABAA receptors on cerebellar granule cells as determined by a quantitative immunogold method,” Journal of Neuroscience, vol. 15, no. 4, pp. 2948–2960, 1995. View at: Google Scholar
  31. Z. Nusser, J. D. B. Roberts, A. Baude, J. G. Richards, W. Sieghart, and P. Somogyi, “Immunocytochemical localization of the α1 and β2/3 subunits of the GABAA receptor in relation to specific GABAergic synapses in the dentate gyrus,” European Journal of Neuroscience, vol. 7, no. 4, pp. 630–646, 1995. View at: Google Scholar
  32. Y. Kasugai, J. D. Swinny, J. D. B. Roberts et al., “Quantitative localisation of synaptic and extrasynaptic GABAA receptor subunits on hippocampal pyramidal cells by freeze-fracture replica immunolabelling,” European Journal of Neuroscience, vol. 32, no. 11, pp. 1868–1888, 2010. View at: Publisher Site | Google Scholar
  33. B. D. Richardson, L. L. Ling, V. V. Uteshev, and D. M. Caspary, “Extrasynaptic GABAA receptors and tonic inhibition in rat auditory thalamus,” PLoS One, vol. 6, no. 1, article e16508, 2011. View at: Publisher Site | Google Scholar
  34. D. P. Bright, M. I. Aller, and S. G. Brickley, “Synaptic release generates a tonic GABAA receptor-mediated conductance that modulates burst precision in thalamic relay neurons,” Journal of Neuroscience, vol. 27, no. 10, pp. 2560–2569, 2007. View at: Publisher Site | Google Scholar
  35. W. Wisden, D. J. Laurie, H. Monyer, and P. H. Seeburg, “The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon,” Journal of Neuroscience, vol. 12, no. 3, pp. 1040–1062, 1992. View at: Google Scholar
  36. D. W. Cope, G. Di Giovanni, S. J. Fyson et al., “Enhanced tonic GABAA inhibition in typical absence epilepsy,” Nature Medicine, vol. 15, no. 12, pp. 1392–1398, 2009. View at: Publisher Site | Google Scholar
  37. D. Chandra, F. Jia, J. Liang et al., “GABAA receptor α4 subunits mediate extrasynaptic inhibition in thalamus and dentate gyrus and the action of gaboxadol,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 41, pp. 15230–15235, 2006. View at: Publisher Site | Google Scholar
  38. N. Brown, J. Kerby, T. P. Bonnert, P. J. Whiting, and K. A. Wafford, “Pharmacological characterization of a novel cell line expressing human α4β3δGABAA receptors,” British Journal of Pharmacology, vol. 136, no. 7, pp. 965–974, 2002. View at: Publisher Site | Google Scholar
  39. F. Jia, D. Chandra, G. E. Homanics, and N. L. Harrison, “Ethanol modulates synaptic and extrasynaptic GABAA receptors in the thalamus,” Journal of Pharmacology and Experimental Therapeutics, vol. 326, no. 2, pp. 475–482, 2008. View at: Publisher Site | Google Scholar
  40. F. Jia, M. Yue, D. Chandra et al., “Taurine is a potent activator of extrasynaptic GABAA receptors in the thalamus,” Journal of Neuroscience, vol. 28, no. 1, pp. 106–115, 2008. View at: Publisher Site | Google Scholar
  41. F. Jia, M. Yue, D. Chandra, G. E. Homanics, P. A. Goldstein, and N. L. Harrison, “Isoflurane is a potent modulator of extrasynaptic GABAA receptors in the thalamus,” Journal of Pharmacology and Experimental Therapeutics, vol. 324, no. 3, pp. 1127–1135, 2008. View at: Publisher Site | Google Scholar
  42. D. V. Pow, R. K. P. Sullivan, S. M. Williams, H. L. Scott, P. R. Dodd, and D. Finkelstein, “Differential expression of the GABA transporters GAT-1 and GAT-3 in brains of rats, cats, monkeys and humans,” Cell and Tissue Research, vol. 320, no. 3, pp. 379–392, 2005. View at: Publisher Site | Google Scholar
  43. S. De Biasi, L. Vitellaro-Zuccarello, and N. C. Brecha, “Immunoreactivity for the GABA transporter-1 and GABA transporter-3 is restricted to astrocytes in the rat thalamus. A light and electron- microscopic immunolocalization,” Neuroscience, vol. 83, no. 3, pp. 815–828, 1998. View at: Publisher Site | Google Scholar
  44. R. J. Sutch, C. C. Davies, and N. G. Bowery, “GABA release and uptake measured in crude synaptosomes from Genetic Absence Epilepsy Rats from Strasbourg (GAERS),” Neurochemistry International, vol. 34, no. 5, pp. 415–425, 1999. View at: Publisher Site | Google Scholar
  45. D. A. Richards, T. Lemos, P. S. Whitton, and N. G. Bowery, “Extracellular GABA in the ventrolateral thalamus of rats exhibiting spontaneous absence epilepsy: a microdialysis study,” Journal of Neurochemistry, vol. 65, no. 4, pp. 1674–1680, 1995. View at: Google Scholar
  46. H. L. Payne, W. M. Connelly, J. H. Ives et al., “GABAAα6-containing receptors are selectively compromised in cerebellar granule cells of the ataxic mouse, stargazer,” Journal of Biological Chemistry, vol. 282, no. 40, pp. 29130–29143, 2007. View at: Publisher Site | Google Scholar
  47. P. I. Ortinski, J. R. Turner, A. Barberis et al., “Deletion of the GABAA receptor α1 subunit increases tonic GABAA receptor current: a role for GABA uptake transporters,” Journal of Neuroscience, vol. 26, no. 36, pp. 9323–9331, 2006. View at: Publisher Site | Google Scholar
  48. P. K. Banerjee, E. Hirsch, and O. C. Snead, “γ-hydroxybutyric acid induced spike and wave discharges in rats: relation to high-affinity [3H]γ-hydroxybutyric acid binding sites in the thalamus and cortex,” Neuroscience, vol. 56, no. 1, pp. 11–21, 1993. View at: Publisher Site | Google Scholar
  49. P. K. Banerjee and O. C. Snead, “Involvement of excitatory amino acid mechanisms in γ-hydroxybutyrate model of generalized absence seizures in rats,” Neuropharmacology, vol. 31, no. 10, pp. 1009–1019, 1992. View at: Publisher Site | Google Scholar
  50. V. Crunelli, Z. Emri, and N. Leresche, “Unravelling the brain targets of γ-hydroxybutyric acid,” Current Opinion in Pharmacology, vol. 6, no. 1, pp. 44–52, 2006. View at: Publisher Site | Google Scholar
  51. R. G. Fariello and G. T. Golden, “The THIP-induced model of bilateral synchronous spike and wave in rodents,” Neuropharmacology, vol. 26, no. 2-3, pp. 161–165, 1987. View at: Google Scholar
  52. O. C. Snead, “The γ-hydroxybutyrate model of absence seizures: correlation of regional brain levels of γ-hydroxybutyric acid and γ-butyrolactone with spike wave discharges,” Neuropharmacology, vol. 30, no. 2, pp. 161–167, 1991. View at: Publisher Site | Google Scholar
  53. P. L. Pearl, K. M. Gibson, M. A. Cortez et al., “Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men,” Journal of Inherited Metabolic Disease, vol. 32, no. 3, pp. 343–352, 2009. View at: Publisher Site | Google Scholar
  54. K. M. Gibson, M. Gupta, P. L. Pearl et al., “Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria),” Biological Psychiatry, vol. 54, no. 7, pp. 763–768, 2003. View at: Publisher Site | Google Scholar
  55. K. M. Gibson, E. Christensen, C. Jakobs et al., “The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients,” Pediatrics, vol. 99, no. 4, pp. 567–574, 1997. View at: Google Scholar
  56. P. L. Pearl, K. M. Gibson, M. T. Acosta et al., “Clinical spectrum of succinic semialdehyde dehydrogenase deficiency,” Neurology, vol. 60, no. 9, pp. 1413–1417, 2003. View at: Google Scholar
  57. P. L. Pearl, E. J. Novomy, M. T. Acosta, C. Jakobs, and K. M. Gibson, “Succinic semialdehyde dehydrogenase deficiency in children and adults,” Annals of Neurology, vol. 54, no. 6, pp. S73–S80, 2003. View at: Publisher Site | Google Scholar
  58. B. M. Hogema, M. Gupta, H. Senephansiri et al., “Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase,” Nature Genetics, vol. 29, no. 2, pp. 212–216, 2001. View at: Publisher Site | Google Scholar
  59. M. Gupta, M. Polinsky, H. Senephansiri et al., “Seizure evolution and amino acid imbalances in murine succinate semialdehyde dehydrogenase (SSADH) deficiency,” Neurobiology of Disease, vol. 16, no. 3, pp. 556–562, 2004. View at: Publisher Site | Google Scholar
  60. A. C. Errington, K. M. Gibson, V. Crunelli, and D. W. Cope, “Aberrant GABAA receptor-mediated inhibition in cortico-thalamic networks of succinic semialdehyde dehydrogenase deficient mice,” PLoS One, vol. 6, no. 4, article e19021, 2011. View at: Publisher Site | Google Scholar
  61. D. Giaretta, M. Avoli, and P. Gloor, “Intracellular recordings in pericruciate neurons during spike and wave discharges of feline generalized penicillin epilepsy,” Brain Research, vol. 405, no. 1, pp. 68–79, 1987. View at: Google Scholar
  62. S. Charpier, N. Leresche, J. M. Deniau, S. Mahon, S. W. Hughes, and V. Crunelli, “On the putative contribution of GABAB receptors to the electrical events occuring during spontaneous spike and wave discharges,” Neuropharmacology, vol. 38, no. 11, pp. 1699–1706, 1999. View at: Publisher Site | Google Scholar
  63. P. O. Polack, I. Guillemain, E. Hu, C. Deransart, A. Depaulis, and S. Charpier, “Deep layer somatosensory cortical neurons initiate spike-and-wave discharges in a genetic model of absence seizures,” Journal of Neuroscience, vol. 27, no. 24, pp. 6590–6599, 2007. View at: Publisher Site | Google Scholar
  64. D. Pinault, N. Leresche, S. Charpier et al., “Intracellular recordings in thalamic neurones during spontaneous spike and wave discharges in rats with absence epilepsy,” Journal of Physiology, vol. 509, no. 2, pp. 449–456, 1998. View at: Publisher Site | Google Scholar
  65. P. Golshani, X. B. Liu, and E. G. Jones, “Differences in quantal amplitude reflect GLuR4-subunit number at corticothalamic synapses on two populations of thalamic neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 4172–4177, 2001. View at: Publisher Site | Google Scholar
  66. M. Steriade and D. Contreras, “Relations between cortical and thalamic cellular events during transition from sleep patterns to paroxysmal activity,” Journal of Neuroscience, vol. 15, no. 1, pp. 623–642, 1995. View at: Google Scholar
  67. L. Danober, C. Deransart, A. Depaulis, M. Vergnes, and C. Marescaux, “Pathophysiological mechanisms of genetic absence epilepsy in the rat,” Progress in Neurobiology, vol. 55, no. 1, pp. 27–57, 1998. View at: Publisher Site | Google Scholar
  68. D. A. Hosford and Y. Wang, “Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures,” Epilepsia, vol. 38, no. 4, pp. 408–414, 1997. View at: Publisher Site | Google Scholar
  69. E. Perucca, L. Gram, G. Avanzini, and O. Dulac, “Antiepileptic drugs as a cause of worsening seizures,” Epilepsia, vol. 39, no. 1, pp. 5–17, 1998. View at: Publisher Site | Google Scholar
  70. A. B. Ettinger, O. G. Bernal, M. R. Andriola et al., “Two cases of nonconvulsive status epilepticus in association with tiagabine therapy,” Epilepsia, vol. 40, no. 8, pp. 1159–1162, 1999. View at: Publisher Site | Google Scholar
  71. A. N. Clarkson, B. S. Huang, S. E. MacIsaac, I. Mody, and S. T. Carmichael, “Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke,” Nature, vol. 468, no. 7321, pp. 305–309, 2010. View at: Publisher Site | Google Scholar

Copyright © 2011 Adam C. Errington et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.